Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 5/2024

01-05-2024 | Cytostatic Therapy | Review Aritcle

Increased V-ATPase activity can lead to chemo-resistance in oral squamous cell carcinoma via autophagy induction: new insights

Authors: Ahmadreza Lagzian, Marziye Askari, Melika Sadat Haeri, Nastaran Sheikhi, Sara Banihashemi, Mohsen Nabi-Afjadi, Yalda Malekzadegan

Published in: Medical Oncology | Issue 5/2024

Login to get access

Abstract

Oral squamous cell carcinoma (OSCC) is a cancer type with a high rate of recurrence and a poor prognosis. Tumor chemo-resistance remains an issue for OSCC patients despite the availability of multimodal therapy options, which causes an increase in tumor invasiveness. Vacuolar ATPase (V-ATPase), appears to be one of the most significant molecules implicated in MDR in tumors like OSCC. It is primarily responsible for controlling the acidity in the solid tumors’ microenvironment, which interferes with the absorption of chemotherapeutic medications. However, the exact cellular and molecular mechanisms V-ATPase plays in OSCC chemo-resistance have not been understood. Uncovering these mechanisms can contribute to combating OSCC chemo-resistance and poor prognosis. Hence, in this review, we suggest that one of these underlying mechanisms is autophagy induced by V-ATPase which can potentially contribute to OSCC chemo-resistance. Finally, specialized autophagy and V-ATPase inhibitors may be beneficial as an approach to reduce drug resistance to anticancer therapies in addition to serving as coadjuvants in antitumor treatments. Also, V-ATPase could be a prognostic factor for OSCC patients. However, in the future, more investigations are required to demonstrate these suggestions and hypotheses.
Literature
1.
2.
El Sheikh M. Survival and quality of life for Sudanese oral cancer patients: University College Cork; 2018.
3.
Johnson NW, Gupta B, Speicher DJ, Ray CS, Shaikh MH, Al-Hebshi N, et al. Etiology and risk factors. Oral and oropharyngeal cancer: CRC Press; 2018. p. 19–94.
4.
Tangsiri M, Hheidari A, Liaghat M, Razlansari M, Ebrahimi N, Akbari A, et al. Promising applications of nanotechnology in inhibiting chemo-resistance in solid tumors by targeting epithelial-mesenchymal transition (EMT). Biomed Pharmacother. 2024;170: 115973.PubMedCrossRef
5.
Chaturvedi P, Singhavi H, Malik A, Nair D. Outcome of head and neck squamous cell cancers in low-resource settings: Challenges and opportunities. Otolaryngol Clin North Am. 2018;51(3):619–29.PubMedCrossRef
6.
Saalim M, Sansare K, Karjodkar FR, Johaley S, Ali IK, Sharma SR, et al. The prevalence of oral squamous cell carcinoma with oral submucous fibrosis. J Cancer Res Ther. 2021;17(6):1510–4.PubMedCrossRef
7.
Panarese I, Aquino G, Ronchi A, Longo F, Montella M, Cozzolino I, et al. Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Rev Anticancer Ther. 2019;19(2):105–19.PubMedCrossRef
8.
9.
Zhu Y, Huang R, Wu Z, Song S, Cheng L, Zhu R. Deep learning-based predictive identification of neural stem cell differentiation. Nat Commun. 2021;12(1):2614.PubMedPubMedCentralCrossRef
10.
Cheng Y, Li S, Gao L, Zhi K, Ren W. The molecular basis and therapeutic aspects of cisplatin resistance in oral squamous cell carcinoma. Front Oncol. 2021;11: 761379.PubMedPubMedCentralCrossRef
11.
Pan L, Feng F, Wu J, Fan S, Han J, Wang S, et al. Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells. Pharmacol Res. 2022;181: 106270.PubMedCrossRef
12.
Xu H, Li L, Wang S, Wang Z, Qu L, Wang C, et al. Royal jelly acid suppresses hepatocellular carcinoma tumorigenicity by inhibiting H3 histone lactylation at H3K9la and H3K14la sites. Phytomedicine. 2023:154940.
13.
Sharma M, Astekar M, Soi S, S Manjunatha B, C Shetty D, Radhakrishnan R. pH gradient reversal: an emerging hallmark of cancers. Recent patents on anti-cancer drug discovery. 2015;10(3):244–58.
14.
Gan Y, Xu Y, Zhang X, Hu H, Xiao W, Yu Z, et al. Revisiting Supersaturation of a Biopharmaceutical Classification System IIB Drug: Evaluation via a Multi-Cup Dissolution Approach and Molecular Dynamic Simulation. Molecules. 2023;28(19):6962.PubMedPubMedCentralCrossRef
15.
Otero-Rey EM, Somoza-Martín M, Barros-Angueira F, García-García A. Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene. Oral Oncol. 2008;44(2):193–9.PubMedCrossRef
16.
Eaton AF, Merkulova M, Brown D. The H+-ATPase (V-ATPase): from proton pump to signaling complex in health and disease. Am J Physiol Cell Physiol. 2021;320(3):C392–414.PubMedCrossRef
17.
18.
19.
Gao Y, Liu Y, Liu Y, Peng Y, Yuan B, Fu Y, et al. UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-Mediated chromatin modifications. Cancer Lett. 2021;520:172–183.PubMedCrossRef
20.
Hraběta J, Belhajová M, Šubrtová H, Merlos Rodrigo MA, Heger Z, Eckschlager T. Drug sequestration in lysosomes as one of the mechanisms of chemoresistance of cancer cells and the possibilities of its inhibition. Int J Mol Sci. 2020;21(12):4392.PubMedPubMedCentralCrossRef
21.
Wang Y, Zhang L, Wei Y, Huang W, Li L, Wu A-a, et al. Pharmacological targeting of vacuolar H+-ATPase via subunit V1G combats multidrug-resistant cancer. Cell Chem Biol. 2020;27(11):1359.
22.
Law Z-J, Khoo XH, Lim PT, Goh BH, Ming LC, Lee W-L, et al. Extracellular vesicle-mediated chemoresistance in oral squamous cell carcinoma. Front Mol Biosci. 2021;8: 629888.PubMedPubMedCentralCrossRef
23.
Kiyoshima T, Yoshida H, Wada H, Nagata K, Fujiwara H, Kihara M, et al. Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. PLoS ONE. 2013;8(11): e80998.PubMedPubMedCentralCrossRef
24.
Dong Y, Zhu G, Wang S-F, Keon KA, Rubinstein JL, Zeng S-X, et al. Toosendanin, a novel potent vacuolar-type H+-translocating ATPase inhibitor, sensitizes cancer cells to chemotherapy by blocking protective autophagy. Int J Biol Sci. 2022;18(7):2684.PubMedPubMedCentralCrossRef
25.
Zhang Y, Mengnan Z, Benke L, Zhang B, Bing C, Yuanyuan W, et al. Ephedra Herb extract ameliorates adriamycin-induced nephrotic syndrome in rats via the CAMKK2/AMPK/mTOR signaling pathway. Chin J Nat Med. 2023;21(5):371–82.PubMed
26.
Kulshrestha A, Katara GK, Ibrahim SA, Riehl VE, Schneiderman S, Bilal M, et al. In vivo anti-V-ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses. Mol Oncol. 2020;14(10):2436–54.PubMedPubMedCentralCrossRef
27.
Zhu L, Smith PP, Boyes SG. pH-responsive polymers for imaging acidic biological environments in tumors. J Polym Sci B Polym Phys. 2013;51:1062.CrossRef
28.
de Bem PB, Nunes JS, da Silva VP, Laureano NK, Gonçalves DR, Machado IS, et al. The role of tumor acidification in aggressiveness, cell dissemination and treatment resistance of oral squamous cell carcinoma. Life Sci. 2022;288: 120163.CrossRef
29.
Huber V, Camisaschi C, Berzi A, Ferro S, Lugini L, Triulzi T, et al. Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation. Seminars Cancer Biol. 2017;43:74.CrossRef
30.
Alshaker HA, Matalka KZ. IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors. Cancer Cell Int. 2011;11(1):1–12.CrossRef
31.
32.
Mostafavi S, Zalpoor H, Hassan ZM. The promising therapeutic effects of metformin on metabolic reprogramming of cancer-associated fibroblasts in solid tumors. Cell Mol Biol Lett. 2022;27(1):1–24.CrossRef
33.
Pilon-Thomas S, Kodumudi KN, El-Kenawi AE, Russell S, Weber AM, Luddy K, et al. Neutralization of tumor acidity improves antitumor responses to immunotherapy. Can Res. 2016;76(6):1381–90.CrossRef
34.
Tong L, Yue P, Yang Y, Huang J, Zeng Z, Qiu W. Motility and mechanical properties of dendritic cells deteriorated by extracellular acidosis. Inflammation. 2021;44:737–45.PubMedCrossRef
35.
Worsley CM, Veale RB, Mayne ES. The acidic tumour microenvironment: Manipulating the immune response to elicit escape. Hum Immunol. 2022;83(5):399–408.PubMedCrossRef
36.
Cao J, Chen C, Wang Y, Chen X, Chen Z, Luo X. Influence of autologous dendritic cells on cytokine-induced killer cell proliferation, cell phenotype and antitumor activity in vitro. Oncol Lett. 2016;12(3):2033–7.PubMedPubMedCentralCrossRef
37.
Chen L, He Y, Zhu J, Zhao S, Qi S, Chen X, et al. The roles and mechanism of m6A RNA methylation regulators in cancer immunity. Biomed Pharmacother. 2023;163: 114839.PubMedCrossRef
38.
Lv C, Yang X, Yu B, Ma Q, Liu B, Liu Y. Blocking the Na+/H+ exchanger 1 with cariporide (HOE642) reduces the hypoxia-induced invasion of human tongue squamous cell carcinoma. Int J Oral Maxillofac Surg. 2012;41(10):1206–10.PubMedCrossRef
39.
Zhou J, Guo T, Zhou L, Bao M, Wang L, Zhou W, et al. The ferroptosis signature predicts the prognosis and immune microenvironment of nasopharyngeal carcinoma. Sci Rep. 2023;13(1):1861.PubMedPubMedCentralCrossRef
40.
Hu J, Li G, Liu Z, Ma H, Yuan W, Lu Z, et al. Bicarbonate transporter SLC4A7 promotes EMT and metastasis of HNSCC by activating the PI3K/AKT/mTOR signaling pathway. Mol Carcinogenesis. 2023;62:628.CrossRef
41.
Swenson ER. Carbonic anhydrase inhibitors and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol. 2006;151(2–3):209–16.PubMedCrossRef
42.
Chu Y-H, Su C-W, Hsieh Y-S, Chen P-N, Lin C-W, Yang S-F. Carbonic anhydrase III promotes cell migration and epithelial-mesenchymal transition in oral squamous cell carcinoma. Cells. 2020;9(3):704.PubMedPubMedCentralCrossRef
43.
Ivanov S, Liao S-Y, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol. 2001;158(3):905–19.PubMedPubMedCentralCrossRef
44.
Choi S-W, Kim J-Y, Park J-Y, Cha I-H, Kim J, Lee S. Expression of carbonic anhydrase IX is associated with postoperative recurrence and poor prognosis in surgically treated oral squamous cell carcinoma. Hum Pathol. 2008;39(9):1317–22.PubMedCrossRef
45.
Akocak S, Güzel-Akdemir Ö, Sanku RKK, Russom SS, Iorga BI, Supuran CT, et al. Pyridinium derivatives of 3-aminobenzenesulfonamide are nanomolar-potent inhibitors of tumor-expressed carbonic anhydrase isozymes CA IX and CA XII. Bioorg Chem. 2020;103: 104204.PubMedPubMedCentralCrossRef
46.
Ivanov SV, Kuzmin I, Wei M-H, Pack S, Geil L, Johnson BE, et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci. 1998;95(21):12596–601.PubMedPubMedCentralCrossRef
47.
Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, et al. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin Cancer Res. 2001;7(11):3399–403.PubMed
48.
Hedley D, Pintilie M, Woo J, Morrison A, Birle D, Fyles A, et al. Carbonic anhydrase IX expression, hypoxia, and prognosis in patients with uterine cervical carcinomas. Clin Cancer Res. 2003;9(15):5666–74.PubMed
49.
Daunys S, Petrikaitė V. The roles of carbonic anhydrases IX and XII in cancer cell adhesion, migration, invasion and metastasis. Biol Cell. 2020;112(12):383–97.PubMedCrossRef
50.
Chien M-H, Ying T-H, Hsieh Y-H, Lin C-H, Shih C-H, Wei L-H, et al. Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol. 2012;48(5):417–23.PubMedCrossRef
51.
Pamarthy S, Kulshrestha A, Katara GK, Beaman KD. The curious case of vacuolar ATPase: regulation of signaling pathways. Mol Cancer. 2018;17:1–9.CrossRef
52.
Huang L, Lu Q, Han Y, Li Z, Zhang Z, Li X. ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol. 2012;7(1):1–7.CrossRef
53.
Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Diz PG, Rey JMG, García-García A. Multidrug resistance in oral squamous cell carcinoma: the role of vacuolar ATPases. Cancer Lett. 2010;295(2):135–43.PubMedCrossRef
54.
Ghaly AM, Elshenshawy HMA, Abd El Hafez A, Ibrahim MMA, El-Sissi AAI. The prognostic role of hypoxia and the microenvironmental acidity in chemo-radio resistance in oral squamous cell carcinoma patients. Acta Biomed. 2023;94(3):e20237114.
55.
Logozzi M, Spugnini E, Mizzoni D, Di Raimo R, Fais S. Extracellular acidity and increased exosome release as key phenotypes of malignant tumors. Cancer Metastasis Rev. 2019;38:93–101.PubMedCrossRef
56.
Pérez-Sayáns M, García-García A, Reboiras-López MD, Gándara-Vila P. Role of V-ATPases in solid tumors: importance of the subunit C. Int J Oncol. 2009;34(6):1513–20.PubMedCrossRef
57.
Kobliakov V. The role of extra-and intracellular pH values in regulation of the tumor process. Cell and Tissue Biology. 2022;16(2):114–20.CrossRef
58.
Zheng T, Jäättelä M, Liu B. pH gradient reversal fuels cancer progression. Int J Biochem Cell Biol. 2020;125: 105796.PubMedCrossRef
59.
Whitton B. Investigating the role of vacuolar-ATPase (V-ATPase) in cancer: University of Southampton; 2020.
60.
Sennoune SR, Bakunts K, Martínez GM, Chua-Tuan JL, Kebir Y, Attaya MN, et al. Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol. 2004;286(6):C1443–52.PubMedCrossRef
61.
Capecci J. Function of Plasma Membrane V-ATPases in Breast Tumor Cell Invasion: Tufts University-Graduate School of Biomedical Sciences; 2014.
62.
Nishi T, Forgac M. The vacuolar (H+)-ATPases—nature’s most versatile proton pumps. Nat Rev Mol Cell Biol. 2002;3(2):94–103.PubMedCrossRef
63.
Su KL. The Role of Plasma Membrane V-ATPases in Breast Cancer Metastasis: Tufts University-Graduate School of Biomedical Sciences; 2021.
64.
Boedtkjer E. Ion channels, transporters, and sensors interact with the acidic tumor microenvironment to modify cancer progression. From Malignant Transformation to Metastasis: Ion Transport in Tumor Biology. 2021:39–84.
65.
Di Pompo G, Cortini M, Baldini N, Avnet S. Acid microenvironment in bone sarcomas Cancers. 2021;13(15):3848.PubMed
66.
Fliegel L. Role of pH regulatory proteins and dysregulation of pH in prostate cancer. From Malignant Transformation to Metastasis: Ion Transport in Tumor Biology. 2020:85–110.
67.
Nelson N, Perzov N, Cohen A, Hagai K, Padler V, Nelson H. The cellular biology of proton-motive force generation by V-ATPases. J Exp Biol. 2000;203(1):89–95.PubMedCrossRef
68.
69.
70.
Thews O, Riemann A. Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer Metastasis Rev. 2019;38:113–29.PubMedCrossRef
71.
72.
Lorenzo Pouso AI, González-Moles MÁ, Ramos-García P, Pérez SM. The Immunohistochemical Landscape of the Hypoxia-Related Proteins in Oral Squamous Cell Carcinoma. Cham: Springer; 2022.CrossRef
73.
Lorenzo-Pouso AI, Castelo-Baz P, Pérez-Sayáns M, Lim J, Leira Y. Autophagy in periodontal disease: Evidence from a literature review. Arch Oral Biol. 2019;102:55–64.PubMedCrossRef
74.
Vitavska O, Wieczorek H, Merzendorfer H. A novel role for subunit C in mediating binding of the H+-V-ATPase to the actin cytoskeleton. J Biol Chem. 2003;278(20):18499–505.PubMedCrossRef
75.
Tripathi A, Misra S. Vacuolar ATPase (V-ATPase) Proton Pump and Its Significance in Human Health. Ion Transporters-From Basic Properties to Medical Treatment: IntechOpen; 2022.
76.
Sennoune SR, Martinez-Zaguilan R. Plasmalemmal vacuolar H+-ATPases in angiogenesis, diabetes and cancer. J Bioenerg Biomembr. 2007;39:427–33.PubMedCrossRef
77.
Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A, et al. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Reports. 2022;5(12): e1291.PubMedCrossRef
78.
Seebacher NA, Krchniakova M, Stacy AE, Skoda J, Jansson PJ. Tumour microenvironment stress promotes the development of drug resistance. Antioxidants. 2021;10(11):1801.PubMedPubMedCentralCrossRef
79.
Pérez-Sayáns M, Somoza-Martín JM, Barros-Angueira F, Rey JMG, García-García A. V-ATPase inhibitors and implication in cancer treatment. Cancer Treat Rev. 2009;35(8):707–13.PubMedCrossRef
80.
Becelli R, Renzi G, Morello R, Altieri F. Intracellular and extracellular tumor pH measurement in a series of patients with oral cancer. J Craniofacial Surg. 2007;18(5):1051–4.CrossRef
81.
Hamm R, Sugimoto Y, Steinmetz H, Efferth T. Resistance mechanisms of cancer cells to the novel vacuolar H+-ATPase inhibitor archazolid B. Invest New Drugs. 2014;32:893–903.PubMedCrossRef
82.
Tavares-Valente D, Sousa B, Schmitt F, Baltazar F, Queirós O. Disruption of pH dynamics suppresses proliferation and potentiates doxorubicin cytotoxicity in breast cancer cells. Pharmaceutics. 2021;13(2):242.PubMedPubMedCentralCrossRef
83.
Martınez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, et al. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 1999;57(9):1037–46.PubMedCrossRef
84.
Chadwick SR, Grinstein S, Freeman SA. From the inside out: ion fluxes at the centre of endocytic traffic. Curr Opin Cell Biol. 2021;71:77–86.PubMedCrossRef
85.
Martínez-Zaguilán R, Raghunand N, Lynch RM, Bellamy W, Martinez GM, Rojas B, et al. pH and drug resistance. I. Functional expression of plasmalemmal V-type H+-ATPase in drug-resistant human breast carcinoma cell lines. Biochem Pharmacol. 1999;57:1037.PubMedCrossRef
86.
Martin-Orozco E, Sanchez-Fernandez A, Ortiz-Parra I, Ayala-San NM. WNT signaling in tumors: the way to evade drugs and immunity. Front Immunol. 2019;10:2854.PubMedPubMedCentralCrossRef
87.
88.
Raghunand N, He X, Van Sluis R, Mahoney B, Baggett B, Taylor C, et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer. 1999;80(7):1005–11.PubMedPubMedCentralCrossRef
89.
Murakami T, Shibuya I, Ise T, Chen ZS, Si A, Nakagawa M, et al. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer. 2001;93(6):869–74.PubMedCrossRef
90.
91.
Zalpoor H, Rezaei M, Yahyazadeh S, Ganjalikhani-Hakemi M. Flt3-ITD mutated acute myeloid leukemia patients and COVID-19: potential roles of autophagy and HIF-1α in leukemia progression and mortality. Hum Cell. 2022;35(4):1304–5.PubMedPubMedCentralCrossRef
92.
93.
94.
Akbari A, Noorbakhsh Varnosfaderani SM, Haeri MS, Fathi Z, Aziziyan F, Yousefi Rad A, et al. Autophagy induced by Helicobacter Pylori infection can lead to gastric cancer dormancy, metastasis, and recurrence: new insights. Hum Cell. 2023;37:139.PubMedCrossRef
95.
Zalpoor H, Bakhtiyari M, Akbari A, Aziziyan F, Shapourian H, Liaghat M, et al. Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights. Cell Communication and Signaling. 2022;20(1):172.PubMedPubMedCentralCrossRef
96.
97.
Dai Z, Zhu B, Yu H, Jian X, Peng J, Fang C, et al. Role of autophagy induced by arecoline in angiogenesis of oral submucous fibrosis. Arch Oral Biol. 2019;102:7–15.PubMedCrossRef
98.
Pangarkar M, Wagh U, Pathak A. Autophagy indicators in oral squamous cell carcinoma. Pathology. 2023;56:59.PubMedCrossRef
99.
Kulkarni B, Gondaliya P, Kirave P, Rawal R, Jain A, Garg R, et al. Exosome-mediated delivery of miR-30a sensitize cisplatin-resistant variant of oral squamous carcinoma cells via modulating Beclin1 and Bcl2. Oncotarget. 2020;11(20):1832.PubMedPubMedCentralCrossRef
100.
Naik PP, Mukhopadhyay S, Panda PK, Sinha N, Das CK, Mishra R, et al. Autophagy regulates cisplatin-induced stemness and chemoresistance via the upregulation of CD 44, ABCB 1 and ADAM 17 in oral squamous cell carcinoma. Cell Prolif. 2018;51(1): e12411.PubMedCrossRef
101.
Li J-M, Li X, Chan LW, Hu R, Zheng T, Li H, et al. Lipotoxicity-polarised macrophage-derived exosomes regulate mitochondrial fitness through Miro1-mediated mitophagy inhibition and contribute to type 2 diabetes development in mice. Diabetologia. 2023;66(12):2368–2386.PubMedCrossRef
102.
Sambandam Y, Ethiraj P, Hathaway-Schrader JD, Novince CM, Panneerselvam E, Sundaram K, et al. Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells. J Cell Physiol. 2018;233(8):6125–34.PubMedPubMedCentralCrossRef
103.
Zhang X, Junior CR, Liu M, Li F, D’Silva NJ, Kirkwood KL. Oral squamous carcinoma cells secrete RANKL directly supporting osteolytic bone loss. Oral Oncol. 2013;49(2):119–28.PubMedCrossRef
104.
Peña-Oyarzún D, Reyes M, Hernández-Cáceres MP, Kretschmar C, Morselli E, Ramirez-Sarmiento CA, et al. Role of autophagy in the microenvironment of oral squamous cell carcinoma. Front Oncol. 2020;10: 602661.PubMedPubMedCentralCrossRef
105.
Ethiraj P, Sambandam Y, Hathaway-Schrader JD, Haque A, Novince CM, Reddy SV. RANKL triggers resistance to TRAIL-induced cell death in oral squamous cell carcinoma. J Cell Physiol. 2020;235(2):1663–73.PubMedCrossRef
106.
Zhao W, Chen C, Zhou J, Chen X, Cai K, Shen M, et al. Inhibition of autophagy promotes the anti-tumor effect of metformin in oral squamous cell carcinoma. Cancers. 2022;14(17):4185.PubMedPubMedCentralCrossRef
107.
Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, et al. Vacuolar H+-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs. 2002;13(3):237–43.PubMedCrossRef
108.
Willingham MC, Cornwell MM, Cardarelli CO, Gottesman MM, Pastan I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and-sensitive KB cells: effects of verapamil and other drugs. Can Res. 1986;46(11):5941–6.
109.
Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Can Res. 2001;61(2):439–44.
110.
Sasazawa Y, Futamura Y, Tashiro E, Imoto M. Vacuolar H+-ATPase inhibitors overcome Bcl-xL-mediated chemoresistance through restoration of a caspase-independent apoptotic pathway. Cancer Sci. 2009;100(8):1460–7.PubMedCrossRef
111.
Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch R, Müller R, Wagner E, et al. V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Mol Cancer Ther. 2014;13(4):926–37.PubMedCrossRef
112.
Perut F, Avnet S, Fotia C, Baglìo SR, Salerno M, Hosogi S, et al. V-ATPase as an effective therapeutic target for sarcomas. Exp Cell Res. 2014;320(1):21–32.PubMedCrossRef
113.
Kataoka T, Muroi M, Ohkuma S, Waritani T, Magae J, Takatsuki A, et al. Prodigiosin 25-C uncouples vacuolar type H+-ATPase, inhibits vacuolar acidification and affects glycoprotein processing. FEBS Lett. 1995;359(1):53–9.PubMedCrossRef
114.
Bowman BJ, Bowman EJ. Mutations in subunit C of the vacuolar ATPase confer resistance to bafilomycin and identify a conserved antibiotic binding site. J Biol Chem. 2002;277(6):3965–72.PubMedCrossRef
115.
Boyd MR, Farina C, Belfiore P, Gagliardi S, Kim JW, Hayakawa Y, et al. Discovery of a novel antitumor benzolactone enamide class that selectively inhibits mammalian vacuolar-type (H+)-atpases. J Pharmacol Exp Ther. 2001;297(1):114–20.PubMed
116.
117.
Huss M, Sasse F, Kunze B, Jansen R, Steinmetz H, Ingenhorst G, et al. Archazolid and apicularen: novel specific V-ATPase inhibitors. BMC Biochem. 2005;6(1):1–10.CrossRef
118.
Fernandes F, Loura L, Fedorov A, Dixon N, Kee T, Prieto M, et al. Binding assays of inhibitors towards selected V-ATPase domains. Biochim Biophys Acta. 2006;1758(11):1777–86.PubMedCrossRef
119.
Li S, Wu Y, Ding Y, Yu M, Ai Z. CerS6 regulates cisplatin resistance in oral squamous cell carcinoma by altering mitochondrial fission and autophagy. J Cell Physiol. 2018;233(12):9416–25.PubMedCrossRef
120.
Wang X, Liu W, Wang P, Li S. RNA interference of long noncoding RNA HOTAIR suppresses autophagy and promotes apoptosis and sensitivity to cisplatin in oral squamous cell carcinoma. J Oral Pathol Med. 2018;47(10):930–7.PubMedCrossRef
121.
Von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, et al. Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem. 2013;288(2):1385–96.CrossRef
122.
Whitton B, Okamoto H, Packham G, Crabb SJ. Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer. Cancer Med. 2018;7(8):3800–11.PubMedPubMedCentralCrossRef
123.
McGuire C, Cotter K, Stransky L, Forgac M. Regulation of V-ATPase assembly and function of V-ATPases in tumor cell invasiveness. Biochim Biophys Acta. 2016;1857(8):1213–8.PubMedPubMedCentralCrossRef
124.
Mauvezin C, Nagy P, Juhász G, Neufeld TP. Autophagosome–lysosome fusion is independent of V-ATPase-mediated acidification. Nat Commun. 2015;6(1):7007.PubMedCrossRef
125.
Guo H, Chitiprolu M, Roncevic L, Javalet C, Hemming FJ, Trung MT, et al. Atg5 disassociates the V1V0-ATPase to promote exosome production and tumor metastasis independent of canonical macroautophagy. Dev Cell. 2017;43(6):716.PubMedCrossRef
126.
Yao X, Chen H, Xu B, Lu J, Gu J, Chen F, et al. The ATPase subunit of ATP6V1C1 inhibits autophagy and enhances radiotherapy resistance in esophageal squamous cell carcinoma. Gene. 2021;768: 145261.PubMedCrossRef
Metadata
Title
Increased V-ATPase activity can lead to chemo-resistance in oral squamous cell carcinoma via autophagy induction: new insights
Authors
Ahmadreza Lagzian
Marziye Askari
Melika Sadat Haeri
Nastaran Sheikhi
Sara Banihashemi
Mohsen Nabi-Afjadi
Yalda Malekzadegan
Publication date
01-05-2024
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2024
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-024-02313-9

Other articles of this Issue 5/2024

Medical Oncology 5/2024 Go to the issue

Original Paper

Physical characterization and bioavailability assessment of 5-fluorouracil-based nanostructured lipid carrier (NLC): In vitro drug release, Hemolysis, and permeability modulation

Original Paper

Probiotic-derived silver nanoparticles target mTOR/MMP-9/BCL-2/dependent AMPK activation for hepatic cancer treatment

Original Paper

Unlocking the potential: phenylboronic acid as a nuclear-targeting boron agent for neutron capture therapy

Review Article

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Original Paper

Identification of small molecule inhibitors against Lin28/let-7 to suppress tumor progression and its alleviation role in LIN28-dependent glucose metabolism

Original Paper

Combination of IFN-gamma with STING agonist and PD-1 immune checkpoint blockade: a potential immunotherapy for gastric cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits